Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with <scp>G</scp>aucher disease type 1: The phase 3 ENGAGE trial
Pramod K. Mistry(Yale University), Michel Peterschmitt, Evgueniy Hadjiev(Alexandrovska Hospital), Мilan Petakov(University of Belgrade), Gregory M. Pastores(New York University), Suma P. Shankar(Emory University), Seymour Packman(University of California, San Francisco), Atul Mehta(National Health Service), Manisha Balwani(Icahn School of Medicine at Mount Sinai), Marwan Ghosn(Hôtel-Dieu de France), Hadhami Ben Turkia(Hôpital La Rabta), Elena Lukina(National Medical Research Center for Hematology), Sumita Danda(Christian Medical College & Hospital), Sarit Assouline(Jewish General Hospital), Andres Ortega, Regina Tayag(Promega (United States)), Hagit Baris(Tel Aviv University), Sebastiaan J.M. Gaemers(Sanofi (Netherlands))
Cited by 99
Related Papers
Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper–transporting ATPase
|Nature Genetics|1993|1.4k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555